Zimmer Biomet Holdings (ZBH): Sales Miss Was Disappointing But Now Its In The Stock - Leerink

November 1, 2016 7:05 AM EDT
Get Alerts ZBH Hot Sheet
Price: $105.28 +0.79%

Rating Summary:
    24 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 19 | Down: 33 | New: 11
Trade ZBH Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst, Richard Newitter, reiterated his Outperform rating on shares of Zimmer Biomet (NYSE: ZBH) but cut the price target to $136 from $150.

The analyst thinks ZBH’s 3Q sales miss was disappointing but considering the 14% pullback, with ZBH back at a ~6x P/E discount to the large cap MedTech avg., the valuation appears to be disconnected from the company’s double digit EPS growth prospects and longer-term mid single digit top-line potential.

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.

Shares of Zimmer Biomet closed at $105.40 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Add Your Comment